Skip to content
Inciteful Med

Diagnosis & Genetics: Reading Your Report

Last updated:

Gaucher disease is diagnosed via a blood test measuring beta-glucosidase enzyme activity, which is typically under 15% of normal. Genetic sequencing of the GBA1 gene confirms the diagnosis by identifying mutations like N370S. Bone marrow biopsies are no longer necessary for diagnosis.

Key Takeaways

  • • The beta-glucosidase enzyme activity assay is the gold standard for confirming a Gaucher disease diagnosis.
  • • Gaucher disease is caused by mutations in the GBA1 gene, such as N370S (Type 1) and L444P (Type 2/3).
  • • Bone marrow biopsies are invasive and no longer required for diagnosis thanks to modern blood tests.
  • • Lyso-Gb1 is the most sensitive biomarker used to track disease activity and treatment response.
  • • Individuals of Ashkenazi Jewish descent have a significantly higher carrier rate (1 in 15) than the general population.

Understanding your diagnostic report is a key step in managing Gaucher disease. While the terms and numbers can seem like a different language, they provide a roadmap for your care. Today, diagnosis is faster and less invasive than it used to be, relying on blood tests rather than bone marrow procedures [1][2].

The Gold Standard: The Enzyme Assay

The first and most important test for Gaucher disease is an enzyme activity assay [1].

  • What it measures: This test looks at the activity level of the enzyme beta-glucosidase (also called glucocerebrosidase) in white blood cells [1].
  • The result: In people with Gaucher disease, this enzyme activity is significantly lower than normal—usually less than 15% of the typical range [1]. A low result on this test is the “gold standard” that confirms the diagnosis [3].

Genetics: Decoding Your GBA1 Report

Once the enzyme assay confirms the disease, doctors perform GBA1 gene sequencing to identify the specific mutations [1]. Your report will likely use two different naming systems (legacy and modern) [4].

Common Mutation Legacy Name Modern HGVS Name Association
N370S p.N370S p.Asn409Ser Type 1 (Non-neuronopathic) [4][5]
L444P p.L444P p.Leu483Pro Type 2/3 (Neuronopathic) [4][6]
  • Autosomal Recessive Inheritance: Gaucher is an “autosomal recessive” condition. This means you must have two mutations (one from each parent) to have the disease [7][8].
  • The 25% Rule (Per Pregnancy): If two carriers have a child, there is a 25% chance that specific pregnancy will result in a child with Gaucher disease, a 50% chance the child will be a carrier, and a 25% chance they will have no mutations [8]. This risk resets for every pregnancy—it does not mean “1 out of 4 children.”

Biomarkers: Tracking the Disease

Think of biomarkers as the “dashboard lights” for Gaucher disease. They tell your doctor how active the disease is and how well treatment is working [9][10].

  • Lyso-Gb1 (Glucosylsphingosine): This is the modern, most sensitive marker used today [11][12]. It measures the toxic byproduct that builds up in the blood. Doctors use it to confirm the diagnosis and monitor your response to treatment over time [13][9].
  • Chitotriosidase (CHITO): This is an older marker. While it can be helpful, it is less specific than Lyso-Gb1 and cannot be used in the roughly 6% of the population who naturally lack the gene to produce this enzyme [13][14].

Family Planning and Carriers

Gaucher disease is much more common in certain populations. Among individuals of Ashkenazi Jewish descent, the disease incidence is approximately 1 in 800, compared to about 1 in 40,000–60,000 in the general population [15][16].

Because the carrier rate is high in this community, many people are carriers without knowing it. It is recommended that siblings and first-degree relatives of a newly diagnosed person speak with a genetic counselor about their own risks and screening options [17][8]. For couples who are both carriers, Pre-implantation Genetic Diagnosis (PGD) during IVF is an option to prevent passing the disease to their children.

A Note on Bone Marrow Biopsy

In the past, a bone marrow biopsy was often used to find “Gaucher cells.” However, this is an invasive procedure and is no longer required for a diagnosis [2][18]. Blood-based enzyme and genetic tests are safer, faster, and more accurate [18][19]. Bone marrow exams are now typically only used if a doctor needs to rule out other blood conditions [18].

Frequently Asked Questions

What is the main test to diagnose Gaucher disease?
The enzyme activity assay is the gold standard test. It measures the level of beta-glucosidase in white blood cells. In people with Gaucher disease, this activity is significantly lower than normal, usually less than 15%.
What do mutations like N370S and L444P mean on my report?
N370S and L444P are specific mutations in the GBA1 gene found in your DNA. N370S is commonly associated with Type 1 (non-neurological) Gaucher disease, while L444P is often linked to Type 2 or 3, which can affect the nervous system.
Do I need a bone marrow biopsy for diagnosis?
No, a bone marrow biopsy is no longer required to diagnose Gaucher disease. Doctors now use blood tests for enzyme activity and genetic sequencing because they are faster, safer, and more accurate than invasive biopsies.
What is the Lyso-Gb1 test and why is it important?
Lyso-Gb1 (glucosylsphingosine) is a biomarker measured in the blood that acts like a dashboard light for the disease. High levels confirm the diagnosis, and doctors track this number over time to see how well treatment is working.
If I am a carrier, will my children inherit the disease?
Gaucher disease is an autosomal recessive condition. If both parents are carriers, there is a 25% chance with each pregnancy that the child will have the disease, and a 50% chance the child will be a carrier like their parents.

Questions for Your Doctor

  • • Which nomenclature was used for my (or my child’s) mutation report—the legacy 'N370S' style or the newer 'Asn409Ser' style?
  • • What is the current Lyso-Gb1 level, and what is our target goal for this marker once treatment begins?
  • • Is the enzyme activity assay result low enough to confirm the diagnosis definitively without further testing?
  • • Given my (or my child's) specific mutations, what is the calculated risk for bone issues or neurological involvement?
  • • Should other family members, such as siblings or cousins, be screened for carrier status?

Questions for You

  • • Have any of my blood relatives been diagnosed with Gaucher disease, Parkinson's, or chronic blood issues?
  • • How much do I want to know about the long-term genetic risks, such as the associated risk for Parkinson's disease later in life?
  • • What is the most confusing part of the genetic report that I need the doctor to explain again?
  • • Am I comfortable with the idea of genetic counseling for myself or my family members?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Gaucher disease: A review].

    Nguyen Y, Stirnemann J, Belmatoug N

    La Revue de medecine interne 2019; (40(5)):313-322 doi:10.1016/j.revmed.2018.11.012.

    PMID: 30638965
  2. 2

    Hematological manifestations and complications of Gaucher disease.

    Revel-Vilk S, Szer J, Zimran A

    Expert review of hematology 2021; (14(4)):347-354 doi:10.1080/17474086.2021.1908120.

    PMID: 33759681
  3. 3

    [Diagnostic journey of type 1 Gaucher Disease patients: A survey including internists and hematologists].

    Deriaz S, Serratrice C, Lidove O, et al.

    La Revue de medecine interne 2019; (40(12)):778-784 doi:10.1016/j.revmed.2019.07.011.

    PMID: 31500934
  4. 4

    Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene.

    Lepe-Balsalobre E, Santotoribio JD, Nuñez-Vazquez R, et al.

    Clinical chemistry and laboratory medicine 2020; (58(12)):2017-2024 doi:10.1515/cclm-2020-0306.

    PMID: 32589593
  5. 5

    Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

    Liu G, Boot B, Locascio JJ, et al.

    Annals of neurology 2016; (80(5)):674-685 doi:10.1002/ana.24781.

    PMID: 27717005
  6. 6

    Establishment of MUi030-A: A human induced pluripotent stem cell line carrying homozygous L444P mutation in the GBA1 gene to study type-3 Gaucher disease.

    Kangboonruang K, Pornsukjantra T, Tong-Ngam P, et al.

    Stem cell research 2023; (73()):103229 doi:10.1016/j.scr.2023.103229.

    PMID: 37890332
  7. 7

    Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a Gaucher mouse model.

    Duffy HBD, Byrnes C, Zhu H, et al.

    JCI insight 2024; (9(21)).

    PMID: 39312723
  8. 8

    Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report.

    Ma M, Wu N, Feng J, et al.

    Frontiers in pediatrics 2025; (13()):1628525 doi:10.3389/fped.2025.1628525.

    PMID: 40791806
  9. 9

    Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors.

    Maines E, Franceschi R, Luppi G, et al.

    Metabolites 2025; (15(7)) doi:10.3390/metabo15070427.

    PMID: 40710527
  10. 10

    Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.

    Cozma C, Cullufi P, Kramp G, et al.

    International journal of molecular sciences 2020; (21(13)) doi:10.3390/ijms21134577.

    PMID: 32605119
  11. 11

    Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.

    Revel-Vilk S, Fuller M, Zimran A

    International journal of molecular sciences 2020; (21(19)) doi:10.3390/ijms21197159.

    PMID: 32998334
  12. 12

    Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.

    Giuffrida G, Markovic U, Condorelli A, et al.

    Orphanet journal of rare diseases 2023; (18(1)):27 doi:10.1186/s13023-023-02623-7.

    PMID: 36782327
  13. 13

    Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1.

    Peterschmitt MJ, Foster MC, Ji AJ, et al.

    Molecular genetics and metabolism 2023; (138(3)):107527 doi:10.1016/j.ymgme.2023.107527.

    PMID: 36739645
  14. 14

    Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.

    Tylki-Szymańska A, Szymańska-Rożek P, Hasiński P, Ługowska A

    Molecular genetics and metabolism 2018; (123(4)):495-500 doi:10.1016/j.ymgme.2018.02.004.

    PMID: 29530534
  15. 15

    A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

    Stirnemann J, Belmatoug N, Camou F, et al.

    International journal of molecular sciences 2017; (18(2)) doi:10.3390/ijms18020441.

    PMID: 28218669
  16. 16

    Gaucher disease epidemiology and natural history: a comprehensive review of the literature.

    Nalysnyk L, Rotella P, Simeone JC, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(2)):65-73 doi:10.1080/10245332.2016.1240391.

    PMID: 27762169
  17. 17

    Enzyme Replacement Therapy in a Gaucher Family.

    Erdem N, Buran T, Berber I, Aydogdu I

    Journal of the National Medical Association 2018; (110(4)):330-333 doi:10.1016/j.jnma.2017.06.013.

    PMID: 30126557
  18. 18

    Two delayed-diagnosis case reports of long-lasting thrombocytopenia with splenomegaly.

    Chen B, Dai W, Xu Y, et al.

    Medicine 2024; (103(34)):e39354 doi:10.1097/MD.0000000000039354.

    PMID: 39183396
  19. 19

    [Gaucher Disease type 1 mimicking immune thrombocytopenia: Role of hyperferritinemia and hypergammaglobulinemia in the initial evaluation of an isolated thrombopenia].

    Faucher B, Seguier J, Swiader L, et al.

    La Revue de medecine interne 2019; (40(10)):680-683 doi:10.1016/j.revmed.2019.05.013.

    PMID: 31213336

This guide explains Gaucher disease diagnostic terminology for educational purposes. Your genetic counselor and doctor are the best sources for interpreting your specific genetic report.

Stay up to date

Get notified when new research about Gaucher Disease is published.

No spam. Unsubscribe anytime.